CML patients also express higher levels of programed death receptor ligand 1 (PD-L1) on myeloid cells (including also CD34+ stem cells), compared to control subject cells, and its receptor PD-1 is expressed on T-cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.